These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8510937)

  • 1. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
    Jackson PK; Paskind M; Baltimore D
    Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.
    Van Etten RA; Debnath J; Zhou H; Casasnovas JM
    Oncogene; 1995 May; 10(10):1977-88. PubMed ID: 7539119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
    Mysliwiec T; Perego R; Kruh GD
    Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An intramolecular SH3-domain interaction regulates c-Abl activity.
    Barilá D; Superti-Furga G
    Nat Genet; 1998 Mar; 18(3):280-2. PubMed ID: 9500553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity.
    Juang JL; Hoffmann FM
    Oncogene; 1999 Sep; 18(37):5138-47. PubMed ID: 10498863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
    Brasher BB; Roumiantsev S; Van Etten RA
    Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of the c-Abl and Bcr-Abl tyrosine kinases.
    Hantschel O; Superti-Furga G
    Nat Rev Mol Cell Biol; 2004 Jan; 5(1):33-44. PubMed ID: 14708008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
    Nagar B; Hantschel O; Seeliger M; Davies JM; Weis WI; Superti-Furga G; Kuriyan J
    Mol Cell; 2006 Mar; 21(6):787-98. PubMed ID: 16543148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C-terminal SH3 domain of the mouse c-Crk protein negatively regulates tyrosine-phosphorylation of Crk associated p130 in rat 3Y1 cells.
    Ogawa S; Toyoshima H; Kozutsumi H; Hagiwara K; Sakai R; Tanaka T; Hirano N; Mano H; Yazaki Y; Hirai H
    Oncogene; 1994 Jun; 9(6):1669-78. PubMed ID: 8183562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
    Mosialos G; Gilmore TD
    Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain.
    Fujita A; Shishido T; Yuan Y; Inamoto E; Narumiya S; Watanabe N
    Mol Pharmacol; 2009 Jan; 75(1):75-84. PubMed ID: 18835981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site.
    de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
    Oncogene; 1997 Feb; 14(5):507-13. PubMed ID: 9053848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded.
    Buffa P; Manzella L; Consoli ML; Messina A; Vigneri P
    Proteins; 2007 Apr; 67(1):1-11. PubMed ID: 17211892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes.
    Hevezi P; Alin K; Goff SP
    Oncogene; 1993 Sep; 8(9):2413-23. PubMed ID: 8361756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mutation within the kinase domain of v-abl gene responsible for temperature-sensitive colony-forming ability in soft agar.
    Soma T; Tsukada S; Oka Y; Kishimoto T; Sugiyama H
    Virology; 1993 Apr; 193(2):967-70. PubMed ID: 8460498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of human c-Abl tyrosine kinase activity and regulation in S. pombe.
    Walkenhorst J; Goga A; Witte ON; Superti-Furga G
    Oncogene; 1996 Apr; 12(7):1513-20. PubMed ID: 8622867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic activation of v-kit involves deletion of a putative tyrosine-substrate interaction site.
    Herbst R; Munemitsu S; Ullrich A
    Oncogene; 1995 Jan; 10(2):369-79. PubMed ID: 7530827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK.
    Jung JH; Pendergast AM; Zipfel PA; Traugh JA
    Biochemistry; 2008 Jan; 47(3):1094-104. PubMed ID: 18161990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
    Groysman M; Nagano M; Shaanan B; Katzav S
    Oncogene; 1998 Sep; 17(12):1597-606. PubMed ID: 9794237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.